GRANULES

Dec 12 (Reuters) - Granules India Ltd GRAN.NS:

• UNIT RECEIVES EIR FROM FDA

Source text: ID:nNSE7p3B0h

Further company coverage: GRAN.NS

(([email protected];))

Nov 13 (Reuters) - Granules India Ltd GRAN.NS:

• Q2 CONSOL PROFIT 1.31 BILLION RUPEES

• Q2 CONSOL TOTAL REVENUE FROM OPERATIONS 12.97 BILLION RUPEES

Further company coverage: GRAN.NS

(([email protected];;))

June 20 (Reuters) - Granules India Ltd GRAN.NS:

• BONTHAPALLY FACILITY COMPLETES US FDA INSPECTION

• FACILITY COMPLETED FDA INSPECTION WITH ONE 483 OBSERVATION

Source text: ID:nNSEbcFQWR

Further company coverage: GRAN.NS

(([email protected];;))

** Indian pharma stocks .NIPHARM gain 1.4%

** Donald Trump signs executive order directing drugmakers to lower prices of their medicines to align with what other countries pay

** But, the order was not as bad as feared, investors, analysts and drug pricing experts said

** Pharma stocks declined in early trade on Monday after Trump's announcement

** HDFC Securities says generic drugmakers unlikely to have any impact

** Adds Sun Pharma SUN.NS to see some impact of price ceiling on specialty products like psoriasis drug Ilumya and anti-baldness drug Leqselvi

** Glenmark Pharma GLEN.NS, Divi's Laboratories DIVI.NS climb 3% each; SUN rises 0.6%

** Lupin LUPN.NS, Granules India GRAN.NS and Biocon BION.NS gain 2.6%, 3.8% and 1.7% respectively

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

April 10 (Reuters) - Granules India Ltd GRAN.NS:

• CLOSING OF ACQUISITION OF SENN CHEMICALS

Further company coverage: GRAN.NS

(([email protected];))

March 25 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA LTD - BOARD APPROVES INTERNAL RESTRUCTURING PLAN FOR US SUBSIDIARIES

• GRANULES INDIA LTD - NO CHANGE IN ULTIMATE OWNERSHIP OR BUSINESS NATURE IN US

Source text: ID:nBSE3nGBP8

Further company coverage: GRAN.NS

(([email protected];))

March 18 (Reuters) - Granules India Ltd GRAN.NS:

• UNIT GRANULES EUROPE HAS BEEN VOLUNTARILY DISSOLVED

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];;))

** Shares of pharma co Granules India GRAN.NS fall 2.4% to 460 rupees

** Stock among top losers on Nifty Pharma index .NIPHARM

** The US FDA issued a warning letter to co post inspection

** Reports says bird droppings and feathers were found on air purification units, ducts, tank etc

** Flagged issues including lack of written procedures for equipment cleaning, residues and microbial contamination in ducts, risking cross-contamination

** More than 2.2 mln shares change hands, 1.6x its 30-day avg

** Stock down ~21% YTD vs a ~15% drop in NIPHARM

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Feb 28 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - GOT ORDER FOR CLOSURE OF PROCEEDINGS OF INVESTIGATION AFTER PAYMENT OF DUES

Further company coverage: GRAN.NS

(([email protected];))

** Shares of Granules India GRAN.NS climb 2.2% to 520 rupees

** Pharma co says it signed agreement to acquire Switzerland-based Senn Chemicals AG

** Co adds, acquisition is expected to close in the

first half of 2025

** Financial details of the deal was not disclosed

** Stock set to log gains after falling for two straight sessions

** Stock down ~14% YTD vs ~13% fall in broader Nifty Pharma index .NIPHARM

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

Feb 21 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA LTD - TO ACQUIRE 100% EQUITY STAKE IN SENN CHEMICALS AG

• GRANULES: DEAL FOR 1.93 BILLION RUPEES

Source text: ID:nNSE1PXl9y

Further company coverage: GRAN.NS

(([email protected];;))

** Shares of Granules India GRAN.NS rise 3.6% to 565.2 rupees

** Pharma co said on Wednesday its Unit V facility received European Union good manufacturing practice certificate for active pharmaceutical ingredients (APIs) and finished dosages

** Certification implies co has been assessed and deemed to meet EU safety, health and environmental protection requirements

** Audit of the facility was done in Nov 2024, co says

** Stock gained 46% in 2024

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Jan 29 (Reuters) - Granules India Ltd GRAN.NS:

• UNIT V RECEIVES EU GMP CERTIFICATE

• EU AUTHORITY CONDUCTED AUDIT OF GRANULES INDIA UNIT V IN NOVEMBER 2024

Source text: ID:nBSE5nkvmM

Further company coverage: GRAN.NS

(([email protected];;))

Jan 24 (Reuters) - Granules India Ltd GRAN.NS:

• Q3 CONSOL PROFIT 1.18 BILLION RUPEES

• Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 11.38 BILLION RUPEES

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];;))

Dec 17 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - ANNOUNCES FDA APPROVAL FOR ADHD TREATMENT, ADDRESSING DRUG SHORTAGES IN U.S

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];))

Dec 4 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - UPDATE ON US FDA INSPECTION AT GAGILLAPUR FACILITY

• GRANULES INDIA LTD - OAI CLASSIFICATION DOES NOT IMPACT ONGOING MANUFACTURING OR DISTRIBUTION

• GRANULES INDIA LTD - OAI STATUS MAY IMPACT REVIEW OF PENDING SUBMISSIONS FOR NEW PRODUCTS

Source text: ID:nnAPN2FLDZF

Further company coverage: GRAN.NS

(([email protected];))

** Shares of pharmaceuticals maker Granules India GRAN.NS close down 10.3%

** This is only the second session this year that the stock has declined by 10% or more

** Stock top loser on the Nifty Pharma index .NIPHARM, which slips about 0.1%

** US FDA classifies inspection co's Gagillapur facility as 'official action indicated' (OAI); the classification means regulatory or administrative actions are recommended

** Co says it has responded to all observations issued by the US FDA and voluntarily undertaken evaluation of facility, in consultation with external subject matter experts

** Trading vols at 18.4 mln, highest since mid-September

** GRAN stock has risen around 32% YTD, NIPHARM also up about 33%

(Reporting by Vijay Malkar)

(([email protected];))

Nov 8 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - GRANULES INDIA’S UNIT V FACILITY SECURES US FDA EIR WITH 'NO ACTION INDICATED' STATUS

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];))

Nov 6 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA Q2 CONSOL PROFIT 972.3 MILLION RUPEES

• GRANULES INDIA Q2 CONSOL TOTAL REVENUE FROM OPERATIONS 9.67 BILLION RUPEES

Further company coverage: GRAN.NS

(([email protected];))

** Shares of Granules India GRAN.NS fall as much as 16.9% to 562.10 rupees, mark sharpest intraday pct loss since March 23, 2020

** Pharmaceutical manufacturing co says several investors have sought clarification from co on U.S. FDA's observations on its Gagillapur facility

** Adds, it will work with FDA to address issues raised in the observations

** On Saturday, FDA inspection at this facility concluded with six observations

** Stock is witnessing its most active trading session since 2005 listing, with more than 35 mln shares change hands, 12.8x of 30-day avg

** Stock last down 16.6%, cutting YTD gains to 39.2%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Aug 20 (Reuters) - Granules India Ltd GRAN.NS:

• RECEIVES ANDA APPROVAL FOR GLYCOPYRROLATE ORAL SOLUTION

Source text for Eikon: ID:nBSE1TgfBl

Further company coverage: GRAN.NS

(([email protected];))

July 30 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES JUNE-QUARTER CONSOL NET PROFIT 1.35 BILLION RUPEES

• GRANULES JUNE-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 11.80 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: GRAN.NS

(([email protected];))

** Indian pharma stocks .NIPHARM up 5.3% this week, set for best weekly rise since March 2022

** Gains led by top-weighted stock Sun Pharma's SUN.NS 9% weekly jump, index heavyweight Divi's Laboratories' DIVI.NS ~6% jump and Torrent Pharma's TORP.NS 6.3% rise

** Granules India GRAN.NS top pct gainer, rising 11.7%, while Biocon BION.NS up 10%

** Eleven stocks on 20-member Nifty Pharma index .NIPHARM rated "buy" or higher, rest rated "hold" - LSEG data

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

BENGALURU, May 15 (Reuters) - Drugmaker Granules India GRAN.NS posted a 1.6% fall in fourth-quarter revenue on Wednesday, hurt by a decline in paracetamol sales and price erosion.

The company's consolidated revenue fell year-on-year to 11.76 billion rupees (nearly $141 million) for the three months to March 31.

Granules, which focuses on making active pharmaceutical ingredients (API), holds 30% of the global market for Paracetamol. It makes the drug's API as well as the finished dosage - the ready-for-consumption product.

Still, weak sales of the drug and price erosion due to heightened competition hurt its revenue. This is despite analysts expecting Indian API makers, including Granules, to benefit from increasing demand from Europe and the U.S., the industry's biggest markets.

Shares fell as much as 2.6% after it reported its results.

Rivals Glenmark Life Sciences GLEM.NS and Laurus Labs LAUL.NS posted lower fourth-quarter profits.

Glenmark's revenue was hit by issues stemming from the Red Sea crisis while Laurus was challenged by multiple factors including a decline in selling prices of antiretroviral products.

A 9.5% drop in Granules' raw material expenses, meanwhile, helped its quarterly profit climb 8.4% to 1.30 billion rupees.

API makers use a variety of chemicals in their formulations, including hydrochloric acid and chloroform, accounting for a majority of the drug-makers' input costs.

The easing costs had helped its profit marginally climb in the third quarter as well, before which profit fell for two straight quarters.

($1 = 83.4750 Indian rupees)

(Reporting by Varun Hebbalalu in Bengaluru; Editing by Janane Venkatraman )

(([email protected];))

May 1 (Reuters) - Granules India Ltd GRAN.NS:

• GETS TAX ORDER FOR TOTAL AMOUNT AT 2.1 MILLION RUPEES

Source text for Eikon: ID:nBSE7b5pyJ

Further company coverage: GRAN.NS

(([email protected];))

April 30 (Reuters) - Granules India Ltd GRAN.NS:

• RECEIPT OF ANDA APPROVAL FOR COLCHICINE CAPSULES

• US FDA APPROVED ANDA FILED BY UNIT GRANULES PHARMACEUTICALS, INC FOR COLCHICINE CAPSULES

Source text for Eikon: ID:nBSE4HM7xD

Further company coverage: GRAN.NS

(([email protected];))

April 12 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA LTD - US FDA AUDIT FOR GRANULES INDIA’S UNIT V FACILITY RESULTS IN ZERO 483

Source text for Eikon: ID:nBSE953D8d

Further company coverage: GRAN.NS

(([email protected];))

April 3 (Reuters) - Granules India Ltd GRAN.NS:

• UPDATE ON GPI FACILITY

• GPI HAS RECEIVED A COMMUNICATION FROM US FDA INDICATING INSPECTION CLASSIFICATION AS VOLUNTARY ACTION INDICATED

• VIRGINIA UNIT RECEIVED COMMUNICATION FROM US FDA INDICATING INSPECTION CLASSIFICATION AS "VOLUNTARY ACTION INDICATED"

• VAI INSPECTION CLASSIFICATION INDICATES US FDA WILL NOT TAKE OR RECOMMEND REGULATORY OR ENFORCEMENT ACTION

Source text for Eikon: ID:nBSE43Tjxw

Further company coverage: GRAN.NS

(([email protected];))

BENGALURU, Jan 23 (Reuters) - Drug maker Granules India GRAN.NS reported a marginal rise in third-quarter profit on Tuesday, helped by easing raw material costs.

The company's consolidated profit rose 1.6% to 1.26 billion rupees (nearly $15 million), according to an exchange filing.

Granules has seen slowing profit growth since the third quarter of 2022. It reported a fall in profit for the past two quarters as it grappled with soaring costs.

The company reported a 0.6% climb in expenses for the third quarter, helped by a 7% fall in raw material costs. In contrast, expenses ranged between 9% and 17% in the last four quarters.

This resulted in a flat profit margin year-on-year at 11%.

Revenue rose 1% to 11.56 billion rupees, with the fixed dosages segment contributing 66% to the total.

Granules, which focuses on making active pharmaceutical ingredients (API), holds 30% of the global market for Paracetamol. It makes the drug's API and finished dosage, the ready-for-consumption product.

Shares of the company rose as much as 3.2% after the results before paring some gains to trade 2.9% higher.

They climbed about 14% in the December quarter, outperforming a 9% rise in the Nifty Pharma index .NIPHARM.

Rival Glenmark Life Sciences GLEM.NS is also expected to report its third-quarter results on Tuesday.

($1 = 83.0900 Indian rupees)

(Reporting by Manvi Pant and Kashish Tandon in Bengaluru; Editing by Sonia Cheema)

(([email protected]; +918447554364;))

Dec 13 (Reuters) - Granules India Ltd GRAN.NS:

• RECEIVED ANDA APPROVAL FOR PANTOPRAZOLE SODIUM DELAYED- RELEASE TABLETS

Source text for Eikon: ID:nBSE43McLm

Further company coverage: GRAN.NS

(([email protected];))